Study
Tesamorelin significantly reduced visceral fat by about 16% in people with HIV receiving INSTI-based treatments over 12 months.
In plain language
A recent study found that tesamorelin, a medication approved for reducing abdominal fat, can effectively decrease visceral fat in people with HIV who are on modern INSTI-based treatment regimens. Over a 12-month period, those taking tesamorelin saw a reduction of about 16% in visceral fat, which is the fat stored around the organs. This is important because excess visceral fat is linked to health problems like heart disease and diabetes. The study showed that tesamorelin was well-tolerated and did not worsen blood sugar levels, making it a promising option for managing body composition in this group.
Use the full description to understand the study design, methods, and the limits of the findings.
This study was a 12-month randomized, double-blind, placebo-controlled trial involving people with HIV on INSTI-based regimens. Researchers compared tesamorelin to a placebo to see its effect on body fat distribution.
Tesamorelin led to a significant decrease in visceral fat by about 16%, while the placebo group saw an increase.
The medication did not affect subcutaneous fat or BMI, and it was well-tolerated without worsening blood sugar control.
Limitations include the small sample size and short duration, which may not capture long-term effects.
For seniors living with HIV, discussing the use of tesamorelin with healthcare providers could be beneficial for managing abdominal fat.
Open the original publication for the complete methods, outcomes, and source material.
Published October 2024 · DOI 10.1097/QAD.0000000000003965
Opens at the publisher · external site · may require institutional access
The study is a high-quality randomized controlled trial with strong design and bias control. Statistical methods are robust, but transparency could be improved with protocol registration. Conflicts of interest are disclosed but present potential bias. The study is not directly relevant to seniors, focusing on a younger HIV-positive population.
| Category | Score | Rating |
|---|---|---|
| Study Design / Evidence Level | 10.0/10 | |
| Bias & Methods | 10.0/10 | |
| Statistical Integrity | 10.0/10 | |
| Transparency | 5.0/10 | |
| Conflict of Interest Disclosure | 5.0/10 | |
| Replication / External Validation | 0.0/10 | |
| Relevance to Seniors | 0.0/10 | |
| Journal Quality | 10.0/10 |
The study's focus on HIV and modern antiretroviral treatments limits its direct applicability to the senior population, but it provides valuable insights into the effects of tesamorelin in a specific clinical context.
Assessed on the study's full text across 8 quality dimensions; conflict-of-interest disclosures were reviewed.
Build a personalized plan using research-backed studies, conditions, and treatments.